Results 41 to 50 of about 12,608 (240)

Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors

Addiction, 2021
Background and Aims Analysed using classical frequentist hypothesis testing with alpha set to 0.05, the Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) did not find enough evidence to reject the hypothesis of no difference in ...
E. Beard, S. Jackson, R. Anthenelli, N. Benowitz, Lisa B. St. Aubin, T. McRae, D. Lawrence, C. Russ, A. Krishen, A. E. Evins, R. West   +10 more
semanticscholar   +1 more source

Evaluation of reproductive and renal toxicity of varenicline in male rats [PDF]

Iranian Journal of Basic Medical Sciences, 2019
Objective(s): Varenicline is a selective partial agonist for the nicotinic acetylcholine receptor a4b2 subtype, which is widely used to treat smoking addiction. However, there is still no data about its potential toxic effects on tissues.
Fatih OĞUZ, Ali Beytur, Elif Taşlıdere, Hakan Parlakpınar, Hilal Oğuz, Alaaddin Polat, İbrahim Topcu, Nigar Vardi, Engin Burak Selcuk   +8 more
doaj   +1 more source

Stability of varenicline concentration in saliva over twenty-one days at three storage temperatures.

Nicotine & Tobacco Research, 2021
INTRODUCTION Varenicline is the most efficacious drug for smoking cessation; saliva varenicline concentrations can be useful for the evaluation of adherence in smoking cessation trials.
M. Novalen, Meghan J. Chenoweth, Bin Zhao, L. Hawk, R. Tyndale   +4 more
semanticscholar   +1 more source

Varenicline aggravates atherosclerotic plaque formation in nicotine-pretreated ApoE knockout mice due to enhanced oxLDL uptake by macrophages through downregulation of ABCA1 and ABCG1 expression

Journal of Pharmacological Sciences, 2020
Varenicline is a widely used and effective drug for smoking cessation. We previously reported that varenicline aggravates atherosclerosis in apolipoprotein E knockout (ApoE KO) mice.
Mitsuhisa Koga, Yuki Kanaoka, Mana Okamoto, Yuki Nakao, Koshun Inada, Saki Takayama, Yasufumi Kataoka, Atsushi Yamauchi   +7 more
doaj  

Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation

Preventive Medicine Reports, 2015
Objectives: A recent trial showed the clinical benefit of retreatment with varenicline in subjects failing on the initial treatment, or relapsing after initial success.
Lieven Annemans, Sophie Marbaix, Kristiaan Nackaerts, Pierre Bartsch   +3 more
doaj   +1 more source

Varenicline: cardiovascular safety [PDF]

Canadian Medical Association Journal, 2011
Serious methodologic issues limit the reliability and relevance of the results of the analysis by Singh and colleagues, in which they reported an “increased risk of serious adverse cardiovascular events” associated with varenicline based on a meta-analysis of 14 studies.[1][1] First ...
openaire   +3 more sources

Risk of neuropsychiatric adverse events associated with varenicline treatment for smoking cessation among Dutch population: A sequence symmetry analysis

Pharmacoepidemiology and Drug Safety, 2021
Varenicline is an effective treatment for smoking cessation. While clinical trials did not confirm a causal role, case reports suggested a possible link of varenicline with neuropsychiatric adverse drug events (NPAEs).
Yuanyuan Wang, J. Boven, J. Bos, C. Schuiling-Veninga, H. Boezen, B. Wilffert, E. Hak   +6 more
semanticscholar   +1 more source

VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES – FRIEND OR ENEMY?

Рациональная фармакотерапия в кардиологии, 2015
The problem of varenicline use in patients with cardiovascular diseases is discussed. Results of large clinical trials and meta-analyses with varenicline have proven its high efficacy for treatment of nicotine addiction in adults and a small number of ...
Yu. V. Lukina, S. Yu. Martsevich
doaj   +3 more sources

Characteristics of first-time varenicline users – A cross-sectional study in Finnish quitters

BMC Public Health, 2017
Background Varenicline is an efficacious medicine for smoking cessation (SC) but little is known about the characteristics of varenicline users. This study examined the characteristics of first-time (naïve) varenicline users in Finland and compared those
Hanna E. Tervonen, Juha H. O. Turunen, Christine L. Baker, Juha Laine, Kari Linden   +4 more
doaj   +1 more source

A genome-wide association study of nausea incidence in varenicline-treated cigarette smokers.

Nicotine & Tobacco Research, 2021
INTRODUCTION Varenicline is the most efficacious smoking cessation treatment, however long-term cessation rates tend to be
Meghan J. Chenoweth, C. Lerman, J. Knight, R. Tyndale   +3 more
semanticscholar   +1 more source